Please login to the form below

Not currently logged in
Email:
Password:

Yervoy

This page shows the latest Yervoy news and features for those working in and with pharma, biotech and healthcare.

BMS’ Q2 results beat expectations with strong performance across core therapy areas

BMS’ Q2 results beat expectations with strong performance across core therapy areas

Sales of its oncology drugs Opdivo and Yervoy also increased on the same period last year, up by 16% and 38%, respectively.

Latest news

More from news
Approximately 37 fully matching, plus 151 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better long-term survival than the Keytruda/chemotherapy combination which is driving the growth

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    drug Yervoy (ipilimumab) in an early-stage trial.

  • Pharma deals in February 2015 Pharma deals in February 2015

    As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.

  • Pharma deals during July 2014 Pharma deals during July 2014

    In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...